What is the main risk factor impacting Bristol-Myers Squibb's financial outlook?

The most significant risk factor highlighted in this filing is the ongoing patent litigation surrounding PLAVIX®. There is a substantial risk of generic competition, which could materially impact PLAVIX® sales, the company's results of operations, cash flows, financial condition, and liquidity. The settlement agreement with Apotex failed to receive antitrust clearance, leading to increased uncertainty.

How did the company's key products perform in the second quarter of 2006?

Key growth products like PLAVIX® saw an 18% sales increase, ABILIFY® revenue grew 35%, and ERBITUX® sales jumped 76%. However, PRAVACHOL experienced a significant 48% sales decline due to market exclusivity expiration. REYATAZ and SUSTIVA also showed strong double-digit growth.

What is the reason for the decrease in earnings per share?

The decrease in earnings per share is primarily attributed to lower gross margins within the pharmaceutical segment, increased research and development spending, and the impact of significant legal settlements and other charges. The potential loss of PLAVIX® exclusivity also creates a cloud of uncertainty impacting investor sentiment and potentially future earnings.

Has the company implemented any new accounting standards?

Yes, Bristol-Myers Squibb adopted SFAS No. 123(R), Share-Based Payment, effective January 1, 2006. This required the recognition of stock-based compensation expense, leading to higher reported expenses compared to prior periods which used the intrinsic value method. The adoption of this standard increased stock-based compensation expense significantly in Q2 2006.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2006

Summary

Bristol-Myers Squibb Company (BMY) reported net sales of $4.871 billion for the three months ended June 30, 2006, a slight decrease of 0.4% compared to $4.889 billion in the prior year period. For the six months ended June 30, 2006, net sales increased by 1.3% to $9.547 billion from $9.421 billion in the prior year. Earnings from continuing operations for the quarter decreased significantly by 32.6% to $667 million ($0.34 per diluted share) from $991 million ($0.50 per diluted share) in the same period last year. For the six-month period, earnings from continuing operations decreased by 9.7% to $1.381 billion ($0.70 per diluted share) from $1.529 billion ($0.78 per diluted share). The company faced significant headwinds, most notably the impending loss of market exclusivity for its blockbuster drug PLAVIX® due to ongoing patent litigation and potential generic competition. This was a primary driver of investor concern. Despite these challenges, the company saw growth in key products like PLAVIX®, ABILIFY®, and ERBITUX® in their respective product lines, offset by declines in older drugs like PRAVACHOL. The company also incurred increased research and development expenses.

Key Highlights

1Net sales for Q2 2006 were $4.871 billion, remaining relatively flat year-over-year.
2Diluted earnings per share from continuing operations decreased to $0.34 in Q2 2006 from $0.50 in Q2 2005.
3The company is facing significant risks related to the PLAVIX® patent litigation, with potential for generic competition and substantial impact on sales and financial results.
4Sales of key growth drivers PLAVIX®, ABILIFY®, and ERBITUX® showed strong year-over-year increases.
5PRAVACHOL sales declined significantly due to market exclusivity expiration.
6Research and development expenses increased by 14% year-over-year, indicating continued investment in pipeline development.
7The company successfully launched new products ORENCIA and EMSAM®.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2006

Summary

Key Highlights

Frequently Asked Questions